What Is a Pre-Submission Meeting With the FDA and When Should I Request One?

A pre-submission meeting with the FDA is a formal consultation opportunity where medical device manufacturers can receive regulatory guidance before submitting their premarket application. These meetings, also known as Q-Sub meetings, allow companies to clarify regulatory requirements, discuss testing protocols, and validate their submission strategy with FDA reviewers.

The FDA’s Pre-Submission Program provides manufacturers with non-binding feedback that can significantly improve the quality and completeness of their eventual submission. While participation is voluntary, these meetings often streamline the regulatory process and reduce the likelihood of delays during formal review. The following sections address common questions about timing, costs, and strategic considerations for pre-submission meetings.

How much does an FDA pre-submission meeting cost?

FDA pre-submission meetings are provided at no charge to medical device manufacturers. The FDA does not impose fees for Q-Sub meetings, making them an accessible resource for companies of all sizes seeking regulatory guidance.

However, manufacturers should consider the indirect costs associated with preparing for these meetings. Companies typically invest significant internal resources in developing comprehensive meeting packages that include detailed device descriptions, proposed testing protocols, and specific regulatory questions. Additionally, many manufacturers engage regulatory consultants to help prepare meeting materials and develop strategic approaches to maximize the value of FDA interactions.

The preparation timeline for a pre-submission meeting usually spans several weeks to months, depending on the complexity of the device and the scope of questions being addressed. While the FDA meeting itself is free, the investment in thorough preparation often determines the quality and usefulness of the feedback received. Companies should budget for the time and expertise required to create compelling meeting packages that generate actionable guidance from FDA reviewers.

What’s the difference between Q-Sub and other FDA meeting types?

Q-Sub meetings are informal consultations focused on early-stage regulatory guidance, while other FDA meeting types serve more formal purposes within specific regulatory pathways. Q-Sub meetings allow manufacturers to discuss general regulatory strategy, testing requirements, and submission approaches before committing to a particular pathway.

The FDA offers several distinct meeting types beyond Q-Sub consultations. Type A meetings address critical issues that require immediate FDA attention and are typically granted within 30 days. Type B meetings focus on specific regulatory milestones, such as End-of-Phase II meetings for clinical trials or Pre-IDE meetings for investigational device exemptions. Type C meetings provide general guidance on regulatory matters and are similar to Q-Sub meetings but may involve different timelines and formats.

Additionally, the FDA conducts specialized meetings for specific submission types. Pre-PMA meetings help manufacturers prepare for Premarket Approval submissions, while De Novo meetings assist with novel device classifications. Each meeting type has distinct objectives, timelines, and preparation requirements. Q-Sub meetings stand out for their flexibility and broad applicability across different device types and regulatory pathways, making them particularly valuable for early-stage planning and strategy development.

The key distinction lies in timing and formality. Q-Sub meetings occur before manufacturers commit to specific regulatory pathways, while other meeting types typically happen within established submission processes. This early engagement allows companies to make informed decisions about their regulatory strategy and avoid costly missteps later in the development process.

When should you request a pre-submission meeting during device development?

Pre-submission meetings should be requested during the early stages of device development, ideally after completing initial design concepts but before finalizing testing protocols or clinical study designs. This timing allows manufacturers to incorporate FDA feedback into their development plans rather than making costly changes later.

The optimal timing varies depending on device complexity and regulatory pathway. For devices following the 510(k) pathway, manufacturers should consider Q-Sub meetings after identifying potential predicate devices but before conducting substantial equivalence testing. This approach ensures that testing protocols align with FDA expectations and adequately demonstrate device safety and effectiveness compared to predicate devices.

For novel devices that may require PMA submission or De Novo classification, earlier engagement becomes even more critical. These manufacturers should request pre-submission meetings during the concept development phase, before investing in extensive clinical studies or specialized testing. Early FDA input can help clarify classification requirements, identify appropriate regulatory pathways, and establish clinical study designs that generate meaningful data for regulatory review.

Additionally, manufacturers should consider requesting follow-up Q-Sub meetings at key development milestones. As device designs evolve or new data becomes available, subsequent meetings can help validate ongoing regulatory strategies and address emerging questions. The FDA encourages iterative engagement throughout the development process, recognizing that device development often involves multiple design iterations and regulatory considerations.

What questions should you ask in a pre-submission meeting?

Pre-submission meeting questions should focus on clarifying regulatory pathways, testing requirements, and submission strategies specific to your device. Effective questions are specific, well-researched, and designed to generate actionable guidance that directly impacts development and submission planning.

Regulatory pathway questions form the foundation of most pre-submission meetings. Manufacturers should seek confirmation of device classification, appropriate submission types (510(k), PMA, or De Novo), and predicate device selection for substantial equivalence demonstrations. These questions help establish the regulatory framework for subsequent development activities and ensure alignment with FDA expectations from the outset.

Testing and clinical study questions represent another critical area for pre-submission discussions. Manufacturers should present proposed testing protocols and seek FDA input on adequacy, scope, and specific standards or guidance documents that apply to their device. For devices requiring clinical data, questions about study design, endpoints, patient populations, and statistical considerations can significantly improve the likelihood of generating acceptable evidence for regulatory review.

Quality system and manufacturing questions also warrant consideration, particularly for novel devices or those involving new manufacturing processes. Manufacturers can discuss design control requirements, risk management approaches, and quality system implementation strategies. These discussions help ensure that quality systems align with FDA expectations and support successful regulatory submissions.

Finally, manufacturers should ask about submission formatting, content organization, and review timelines. Understanding FDA preferences for data presentation, document structure, and communication protocols can streamline the submission process and reduce the likelihood of administrative delays during formal review.

How MedEnvoy Helps with FDA Pre-Submission Strategy

MedEnvoy provides comprehensive support for FDA pre-submission meetings, leveraging decades of experience working directly with FDA reviewers to maximize the value of these critical interactions. Our regulatory experts help manufacturers develop strategic approaches to FDA engagement that generate actionable guidance and accelerate regulatory timelines.

• Strategic meeting preparation and question development tailored to your specific device and regulatory objectives
• Comprehensive regulatory pathway analysis to ensure appropriate submission strategies
• Expert guidance on testing protocols and clinical study design that align with FDA expectations
• Professional meeting facilitation and follow-up communication with FDA reviewers
• Integration of FDA feedback into ongoing US FDA Agent services and regulatory compliance support

Ready to optimize your FDA pre-submission strategy? Contact our regulatory experts to discuss how we can help you navigate the complexities of FDA engagement and accelerate your path to market clearance.

Related Articles

• What Is a GMP Certificate for Mexico?
• What Responsibilities Does a Swiss Authorized Representative Have?
• Do I Need a Consultant for European Market Entry?
• How Do I Get Approval to Sell Medical Devices in France?
• What are the Fees for Selling Medical Devices in Europe?